Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Seagen Inc.
Incyte Corporation
Seagen Inc.
Revolution Medicines, Inc.
Delcath Systems Inc.
Janssen Research & Development, LLC
Pfizer
Merck Sharp & Dohme LLC
BioNTech SE
Sun Yat-sen University
Hoffmann-La Roche
Summit Therapeutics
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
Amgen
M.D. Anderson Cancer Center
Pfizer
AstraZeneca
Second Affiliated Hospital, School of Medicine, Zhejiang University
Genentech, Inc.
Hoffmann-La Roche
Luye Pharma Group Ltd.
University of Wisconsin, Madison
Replimune Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pfizer
Novartis
UNICANCER
Ono Pharmaceutical Co. Ltd
AstraZeneca
Eli Lilly and Company
Gruppo Oncologico del Nord-Ovest
The Second Hospital of Hebei Medical University
Cardiff Oncology
Peking University Cancer Hospital & Institute
Harbin Medical University
GlaxoSmithKline
Pfizer
Sixth Affiliated Hospital, Sun Yat-sen University
Bristol-Myers Squibb
UNICANCER
City of Hope Medical Center
Gruppo Oncologico del Nord-Ovest
Second Affiliated Hospital, School of Medicine, Zhejiang University
Anbogen Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.